Dennis Jackman, Senior Vice President, Public Affairs at CSL Behring discusses rare disease drug pricing, patient involvement in the drug development process, and drug access.

With regard to the latter issue, Jackman said, “if the community and industry, companies like ours, are successful in developing a rare disease product, then not having access to it because of payment policies that exist or access policies by payers is really tragic. And in some cases we’re seeing discriminatory or harmful elements such as high co-insurance rates for rare disease patients in specialty tiers that that hit rare disease patients much more than they would hit other patients.”

As for pricing, Jackman noted that it is important for drug companies to show the value of the drug rather than focus on pricing.

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.